These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 3179638)

  • 41. Dose response studies and longterm evaluation of auranofin in rheumatoid arthritis.
    Champion GD; Cairns DR; Bieri D; Adena MA; Browne CD; Cohen ML; Day RO; Edmonds JP; Graham GG; de Jager J
    J Rheumatol; 1988 Jan; 15(1):28-34. PubMed ID: 3280795
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neurotoxicity following a very high dose of oral gold (auranofin).
    Gambari P; Ostuni P; Lazzarin P; Tavolato B; Todesco S
    Arthritis Rheum; 1984 Nov; 27(11):1316-7. PubMed ID: 6093822
    [No Abstract]   [Full Text] [Related]  

  • 43. Auranofin: dose-related risk to benefit.
    Weiss TE
    Am J Med; 1983 Dec; 75(6A):128-32. PubMed ID: 6419594
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A stepwise increased dose of auranofin does not influence gastrointestinal side-effects.
    Johannsen F; Brodin U; Emmertsen H; Hansen TM; Faarvang KL; Bugge P; Nielsen GL; Jensen OH; Beyer J; Danneskiold-Samsøe B; Jarner D; Arfeldt E; Krohn L; Nielsen H; Nielsen SE
    Clin Exp Rheumatol; 1997; 15(4):454-5. PubMed ID: 9272314
    [No Abstract]   [Full Text] [Related]  

  • 45. [Gold preparations in therapy of rheumatoid and psoriatic arthritis].
    Nasonova VA; Lukina GV; Sigidin IaA; Badokin VV
    Ter Arkh; 2003; 75(5):88-90. PubMed ID: 12847908
    [No Abstract]   [Full Text] [Related]  

  • 46. Comparison of auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial.
    Ward JR; Williams HJ; Egger MJ; Reading JC; Boyce E; Altz-Smith M; Samuelson CO; Willkens RF; Solsky MA; Hayes SP
    Arthritis Rheum; 1983 Nov; 26(11):1303-15. PubMed ID: 6416259
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Auranofin-induced vasomotor reaction.
    Proudman SM; Cleland LG
    Arthritis Rheum; 1992 Dec; 35(12):1452-4. PubMed ID: 1472122
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gold concentrations and toxicity during oral gold treatment with auranofin.
    Sharma RP; Smillie J; Palmer DG
    Pharmacology; 1985; 30(2):115-20. PubMed ID: 3919401
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of two dosage schedules of gold salts in the treatment of rheumatoid arthritis. Relationship of serum gold levels to therapeutic response.
    Sharp JT; Lidsky MD; Duffy J; Thompson HK; Person BD; Masri AF; Andrianakos AA
    Arthritis Rheum; 1977; 20(6):1179-87. PubMed ID: 409413
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Auranofin. A preliminary review of its pharmacological properties and therapeutic use in rheumatoid arthritis.
    Chaffman M; Brogden RN; Heel RC; Speight TM; Avery GS
    Drugs; 1984 May; 27(5):378-424. PubMed ID: 6426923
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Auranofin: experience to date.
    Blodgett RC
    Am J Med; 1983 Dec; 75(6A):86-9. PubMed ID: 6419601
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Auranofin treatment for adult rheumatoid arthritis. Comparison of 2 mg and 6 mg daily dose.
    Bernhard GC
    J Rheumatol Suppl; 1982; 8():149-53. PubMed ID: 6813477
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A comparative study of auranofin, gold sodium thiomalate, and D-penicillamine in rheumatoid arthritis: a progress report.
    Barraclough D; Brook A; Brooks P; Boyden K; Thomas D; Tymms K
    J Rheumatol Suppl; 1982; 8():197-200. PubMed ID: 6813485
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A 12-month comparative trial of auranofin and D-penicillamine in rheumatoid arthritis.
    Felix-Davies DD; Stewart AM; Wilkinson BR; Bateman JR; Delamere JP
    Am J Med; 1983 Dec; 75(6A):138-41. PubMed ID: 6419596
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An oral gold formulation in rheumatoid arthritis. A 12-month follow-up report.
    Schorn D
    S Afr Med J; 1982 Aug; 62(10):313-6. PubMed ID: 6810477
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Auranofin. Mechanism of action, pharmacokinetics and clinical use. Comparison with injectable gold salts].
    Chamouard JM; Clerc D; Bisson M; Medicis P; Massias P
    Rev Rhum Mal Osteoartic; 1985 Apr; 52(4):277-82. PubMed ID: 3923604
    [No Abstract]   [Full Text] [Related]  

  • 57. Gold colitis induced by auranofin treatment of rheumatoid arthritis: case report and review of the literature.
    Langer HE; Hartmann G; Heinemann G; Richter K
    Ann Rheum Dis; 1987 Oct; 46(10):787-92. PubMed ID: 3318725
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bronchiolitis in a rheumatoid arthritis patient receiving auranofin.
    O'Duffy JD; Luthra HS; Unni KK; Hyatt RE
    Arthritis Rheum; 1986 Apr; 29(4):556-9. PubMed ID: 3085683
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [A comparative evaluation of parenteral and oral preparations of gold and D-penicillamine in the treatment of rheumatoid nephropathy].
    Chichasova NV; Kanevskaia MZ; Slobodina GA; Varshavskiĭ VA; Krel' OV; Krel' AA
    Ter Arkh; 1991; 63(5):97-101. PubMed ID: 1679571
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Comparative study of the effects of auranofin and aurothiomalate on laboratory and clinical indicators in patients with rheumatoid arthritis].
    Vlak T; Stambuk B
    Reumatizam; 1998; 46(1):7-19. PubMed ID: 9921004
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.